firstwordpharmaJuly 23, 2021
Rallybio plans to raise $81 million in its initial public offering by offering 5.8 million shares at a price range of $13 to $15, as reported by NASDAQ.
The company is currently advancing its lead program, RLYB211, in a Phase I/II trial for the treatment of fetal and neonatal alloimmune thrombocytopenia (FNAIT).
RLYB211 is a polyclonal anti-HPA-1a antibody and is expected to report data from its Phase I/II trial this month.
The company also has four preclinical programs, one of which, RLBY212, is also being developed for the treatment of FNAIT, and two of which are being developed to treat complement dysregulation diseases.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: